The Pure ChainTirzepatide
Regulatory status
Copies of commercially available approved drugs. Compounding is restricted under sections 503A and 503B outside a declared shortage. Quoted only on request to verified facilities, who are responsible for confirming their own eligibility.
Summary
Tirzepatide is a 39-residue dual GIP and GLP-1 receptor agonist carrying two aminoisobutyric acid residues and a C20 fatty diacid side chain. The length and the unnatural residues together make it the most difficult synthesis in this catalogue.
Very few manufacturers can hold impurity profiles at the level a regulated facility would accept, and the gap between the cheapest and the qualified quote in this line is larger than for any other molecule we track.
Typical related substances
Typical related substances are deletion sequences at the Aib positions, unacylated and over-acylated species and aggregated forms.
Regulatory note
Copy of a commercially available approved drug. Compounding is restricted under sections 503A and 503B outside a declared shortage.
Regulatory status shown is our current understanding and is not legal advice. Each facility is responsible for confirming eligibility for its own licence type before purchase.